CN104187670A - Special dietary formula for assisting patients with diabetes in regulating blood sugar - Google Patents
Special dietary formula for assisting patients with diabetes in regulating blood sugar Download PDFInfo
- Publication number
- CN104187670A CN104187670A CN201410440468.2A CN201410440468A CN104187670A CN 104187670 A CN104187670 A CN 104187670A CN 201410440468 A CN201410440468 A CN 201410440468A CN 104187670 A CN104187670 A CN 104187670A
- Authority
- CN
- China
- Prior art keywords
- blood sugar
- arabinose
- stachyose
- probiotics
- polydextrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 28
- 210000004369 blood Anatomy 0.000 title claims abstract description 28
- 235000000346 sugar Nutrition 0.000 title claims abstract description 23
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 13
- 235000005911 diet Nutrition 0.000 title claims abstract description 10
- 230000001105 regulatory effect Effects 0.000 title abstract description 4
- 230000000378 dietary effect Effects 0.000 title abstract 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 28
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 23
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 23
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 14
- 239000001259 polydextrose Substances 0.000 claims abstract description 14
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 14
- 229940035035 polydextrose Drugs 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 7
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 13
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 13
- 229920001202 Inulin Polymers 0.000 claims description 12
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 12
- 229940029339 inulin Drugs 0.000 claims description 12
- 240000008892 Helianthus tuberosus Species 0.000 claims description 6
- 235000003230 Helianthus tuberosus Nutrition 0.000 claims description 6
- 230000037213 diet Effects 0.000 claims description 6
- 235000013325 dietary fiber Nutrition 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000011953 bioanalysis Methods 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 16
- 239000008103 glucose Substances 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 11
- 235000013406 prebiotics Nutrition 0.000 abstract description 8
- 239000006041 probiotic Substances 0.000 abstract description 6
- 235000018291 probiotics Nutrition 0.000 abstract description 6
- 229930006000 Sucrose Natural products 0.000 abstract description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 5
- 210000002490 intestinal epithelial cell Anatomy 0.000 abstract description 5
- 210000000813 small intestine Anatomy 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000035790 physiological processes and functions Effects 0.000 abstract description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 abstract description 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 abstract description 2
- 210000004153 islets of langerhan Anatomy 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 abstract 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 235000013681 dietary sucrose Nutrition 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000035479 physiological effects, processes and functions Effects 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 12
- 230000009286 beneficial effect Effects 0.000 description 9
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 239000001573 invertase Substances 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000294142 Vascellum Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000021393 food security Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 235000021071 low fiber diet Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- FZWBNHMXJMCXLU-YRBKNLIBSA-N manninotriose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-YRBKNLIBSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention provides a special dietary formula for assisting patients with diabetes in regulating blood sugar. The special dietary is prepared from the following raw materials by mass fraction: 20-50% of stachyose, 20-30% of synanthrin, 20-30% of polydextrose and 3-10% of L-arabinose, wherein the stachyose, the polydextrose and the synanthrin are prebiotics of intestinal probiotics groups; proliferation of probiotics groups can be prompted; a great number of probiotics are adhered to the intestinal epithelial cells, thereby forming pellicle and preventing absorption of a lot of glucose; probiotics also are capable of accelerating glucose consumption, reducing intestinal glucose and reducing blood sugar; and the L-arabinose is capable of selectively inhibiting the activity of disaccharide decomposition enzymes such as saccharose, maltose and the like in small intestines, playing the role of reducing blood sugar, improving the insulin resistance and protecting islet cells to play a normal physiology function. The probiotics and the L-arabinose are matched, so that special dietary is capable of well assisting the patients with diabetes in regulating blood sugar, and maintaining a healthy physiological state.
Description
Technical field
The invention belongs to special diet field.Utilize stachyose, polydextrose, inulin to impel proliferation of probiotics, and become dominant bacteria and improve intestinal microecology balance, and then reach the object that regulates blood sugar.
Background technology
Along with economic develop rapidly, living condition is greatly improved.Increasing disease is corroding the mankind's health in recent years, finds that by research these diseases more or less have inseparable relation with intestinal microecology.Especially high protein, higher fatty acid, low-fiber diet form have replaced the traditional food mode of thickness combination originally, in addition the pollution of the resource such as air, water now, the factors such as food security and modern medicine abuse of antibiotics, make the subject to severe risks of damage of human body intestinal canal microecological balance.
The multinomial animal experiment research in laboratory, various countries all shows, conditioned pathogen (can be called for short " bad bacterium ") quantity in enteron aisle increases, SCFA produces bacterium, and (being called for short " good bacterium ") reduces, can cause immunotoxin (being mainly endotoxin) to enter blood, and then bring out chronic inflammation, destroy insulin receptor, disturb fat metabolism gene expression, finally cause fat at abdominal cavity and liver bulk deposition, form fat symptom; More seriously, the chronic inflammation that bacterial immune toxin causes not only rests in fat this aspect the destruction of health, this inflammation can continue to destroy large and small blood vessel, finally causes more serious disease, as diabetes, coronary heart disease, apoplexy etc.Intestinal health can not be ignored.Through lot of experiments, expert points out to regulate by appropriate food nutrition, especially increases the nutraceutical absorptions such as prebiotics and can make human body intestinal canal microecosystem restore balance.Studies show that, supplement 3-10 gram of prebiotics every day, and the beneficial bacterium quantity in enteron aisle can roll up.Therefore, the food that has added high-quality prebiotics by eating some, promotes profitable strain growth and breeding, make profitable strain in human body intestinal canal again occupy advantage, recover enteron aisle vigor, promote intestines peristalsis, Accelerating Removal ight soil, the young state of reduction enteron aisle, and then can assist diabetes patient to regulate blood sugar.Stachyose (Stachyose) is a kind of tetrose that nature exists, and is present in kobold, and is distributed widely in legume, belongs to gossypose and belongs to galactosides irreducibility functional oligose.Kobold be grown in that China western part is semiarid, special plant in half prone soil, it is rich in a kind of material-" stachyose " of being described as " healthy baby " and " superpower Oilgosaccharkdes " by World of Food the world of medicine.These meals stachyose used is taking kobold as raw material, through separation and Extraction purifying and come functional oligose.
Pure water threose is white powder, micro-sweet, and sugariness is only 22% of sucrose, clean taste, free from extraneous odour.Stachyose enters after human body, can not be decomposed and absorb by stomach, and can only be utilized by the profitable strain such as Bifidobacterium, Bacillus acidi lactici in human body intestinal canal, promote the growth and breeding of beneficial bacterium, also can promote the absorption of intestines and stomach to the element such as calcium, magnesium, after taking, not produce abdominal distension, quietly moisten intestines and stomach; Simultaneously Bifidobacterium can be in enteron aisle the synthesized human required vitamin B1 of growing, B6, B12, the nutriments such as nicotinic acid, folic acid.Stachyose and other functional oligose are similar, but its outstanding advantage is: it is much better than oligoisomaltose and FOS to the cultivation effect of Bifidobacterium Bifidum, can, with 40 times of speed propagation Bifidobacteriums that increase progressively, therefore be described as again " superpower Oilgosaccharkdes "; In addition, stachyose can also suppress spoilage organisms as the growth of Escherichia coli and C.perfringens, thereby reduces phenol, ammonia that spoilage organisms metabolism produces, the harmful substances such as indoles.At present stachyose is mainly as third generation functional food ingredient, makes an addition in common or health food, plays and regulates intestinal flora balance, improves function of intestinal canal, reduces blood fat, regulates immunity, unique physiological function such as relax bowel.In view of above stachyose is at the many advantages aspect enteron aisle health care, become in recent years a kind of function raw material being popular on health food market.
Along with the raising day by day of living standards of the people, consumer strengthens gradually to intestinal health consciousness, also there is marked change in people's drink structure, the market of high heat beverage glides year by year, and nutrition, health care, the functional strong drinks such as low-sugar drink, sugar-free beverage, tea beverage become the main flow in market gradually.It is that intestinal beneficial bacterium group is as the high activity prebiotics of Bifidobacterium, lactobacillus etc. that the present invention utilizes stachyose, inulin, polydextrose, can impel intestinal beneficial bacterium group growth and breeding, a large amount of probios are attached to intestinal epithelial cell, form one deck overcoat, in order to avoid a large amount of glucose is absorbed; Meanwhile, a large amount of probios can accelerate to consume the glucose in enteron aisle, causes the glucose in enteron aisle to reduce, and then blood-sugar content is reduced.Arabinose can suppress the activity of disaccharide-hydrolysing enzymes in small intestine, and blocking-up human body is taken in sucrose, reduces postprandial blood sugar, alleviates pancreas islet burden, thereby plays the effect of steady blood sugar; Arabinose is synthetic SCFA in large intestine, reduces blood fat and triglycerides, improves human body HDL, removes blood rubbish, dredging vascellum, and in time for each histoorgan provides blood and energy, thus prevention and improve diabetic complication.Be used in conjunction with better effects if with above prebiotics, the invention of this special diet is just meeting people's life requirement now.
Summary of the invention
The present invention has developed a kind of auxiliary diabetes patient and has regulated the special diet of blood sugar, to utilize stachyose, polydextrose and inulin to breed probio, balance intestinal microecology, a large amount of probios is attached to intestinal epithelial cell and can avoids glucose to be absorbed in a large number, can consume the glucose in enteron aisle, and then reduce blood sugar simultaneously; The existence of Arabinose can suppress the activity of disaccharide-hydrolysing enzymes in small intestine, and the absorption of blocking-up sucrose, reduces blood sugar, alleviates pancreas islet burden; Prebiotics and Arabinose acting in conjunction, reach the object of assisting diabetes patient to regulate blood sugar.Its formula is: stachyose 20-50%, inulin 20-30%, polydextrose 20-30% and Arabinose 3-10%, be more than mass fraction than row.Stachyose used is to carry out the functional oligose that separation and Extraction purifying comes taking kobold as raw material, and its purity is not less than 70%; Inulin used is that as a kind of dietary fiber that raw material separation and Extraction purifying comes, wherein soluble dietary fibre content is not less than 90% taking jerusalem artichoke (another name Jerusalem artichoke, Jerusalem artichoke); Polydextrose used is a kind of novel soluble dietary fiber, and its purity is not less than 90%; Arabinose used is a kind of functional sugar that utilizes bioanalysis to extract from corncob string, and its purity is not less than 95%.
After edible meals of the present invention, stachyose, polydextrose and inulin wherein directly arrive caecum, can fast breeding intestinal beneficial bacterium group, accelerate the wriggling of enteron aisle, thereby toxic metabolite material in enteron aisle is drained rapidly, avoid toxic metabolite material to enter blood, entered bio-transformation and increase burden of liver by liver.The stachyose of eating can decompose the multiple immune effect factors such as producing manninotriose, gossypose, melibiose after profitable strain utilization, has higher immunocompetence, can promote the immunocompetence of body; The polydextrose of eating and inulin are produced SCFA as butyric acid, acetic acid and lactic acid etc. by beneficial bacterium fermentation, have reduced enteron aisle pH value, can help opposing to infect, and have formed good intestinal microecology; On this basis, a large amount of beneficial bacteriums are attached to intestinal epithelial cell, form physical barriers and microbial barrier, prevent that enteron aisle from absorbing glucose in a large number, the existence of glucose, accelerate the growth and breeding of beneficial flora, various types of probio quantity is increased severely, further accelerate to consume the glucose in enteron aisle, cause the glucose content in enteron aisle to greatly reduce, it is controlled that body absorbs the glucose entering in blood, reaches hypoglycemic object.
Arabinose is wherein a kind of sweetener low in calories, after human body is taken in, optionally suppress the two carbohydrate-splitting enzyme activity such as invertase and maltose in small intestine, thereby suppress to raise because taking in the blood sugar that sucrose (resolve into glucose under the effect of small intestine invertase and fructose is absorbed) causes; And can improve insulin resistance, the protection islet cells physiological function of bringing into normal play, is strengthening sugar tolerance effect, occurs reducing diabetes, and prevention of obesity, maintains healthy physiological status significant.The mouthfeel of having improved meals in controlling blood sugar, makes it be easier to be accepted.
Therefore, it is to breed intestinal beneficial bacterium group by prebiotics that auxiliary diabetes patient of the present invention regulates the special diet of blood sugar, makes profitable strain amount reproduction in enteron aisle, realizes the preliminary object of intestinal microecology balance; Based on this, be attached in a large number the effect that probio on intestinal epithelial cell plays physical protection and consumption of glucose, in addition Arabinose can assistant hypoglycemic, prevention diabetes, it is controlled that body absorbs the glucose entering in blood, and after blood sugar declines, liver is used for being converted into fatty glycogen also have been reduced, body weight also can be controlled, reaches the final purpose of assisting diabetes patient to regulate blood sugar.
Detailed description of the invention
Below in conjunction with embodiment, so that the present invention is made and being further illustrated.The specific descriptions of embodiment, do not constitute any limitation scope of the present invention.
Embodiment 1:
Method for making: after stachyose, polydextrose, inulin, Arabinose are mixed, filter through 100 mesh sieves, mix rear packing, 5 grams of every pouches, totally 200 pouches.
Embodiment 2:
Method for making: after stachyose, polydextrose, inulin, Arabinose are mixed, filter through 100 mesh sieves, mix rear packing, 5 grams of every pouches, totally 200 pouches.。
Usage: get 1 pouch at every turn, pour in cup, wash open edible by warm water.
Claims (6)
1. auxiliary diabetes patient regulates a special diet formula for blood sugar, it is characterized by: formula comprises stachyose, inulin, polydextrose and Arabinose.
2. as claimed in claim 1, it is characterized by: stachyose 20-50%, inulin 20-30%, polydextrose 20-30%, Arabinose 3-10%, described proportioning is mass fraction.
3. as claimed in claim 1, it is characterized by: stachyose is to carry out the functional oligose that separation and Extraction purifying comes taking kobold as raw material, and its purity is not less than 70%.
4. as claimed in claim 1, it is characterized by: inulin is that as a kind of dietary fiber that raw material separation and Extraction purifying comes, wherein soluble dietary fibre content is not less than 90% taking jerusalem artichoke (another name Jerusalem artichoke, Jerusalem artichoke).
5. as claimed in claim 1, it is characterized by: polydextrose is a kind of novel soluble dietary fiber, and its purity is not less than 90%.
6. as claimed in claim 1, it is characterized by: Arabinose is a kind of functional sugar that utilizes bioanalysis to extract from corncob string, and its purity is not less than 95%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410440468.2A CN104187670A (en) | 2014-09-02 | 2014-09-02 | Special dietary formula for assisting patients with diabetes in regulating blood sugar |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410440468.2A CN104187670A (en) | 2014-09-02 | 2014-09-02 | Special dietary formula for assisting patients with diabetes in regulating blood sugar |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104187670A true CN104187670A (en) | 2014-12-10 |
Family
ID=52073185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410440468.2A Pending CN104187670A (en) | 2014-09-02 | 2014-09-02 | Special dietary formula for assisting patients with diabetes in regulating blood sugar |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104187670A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104939082A (en) * | 2015-06-02 | 2015-09-30 | 西安膳方医药科技有限公司 | Composite prebiotic and preparation method thereof |
| CN105341641A (en) * | 2015-09-28 | 2016-02-24 | 河南科技大学 | Health-care flour capable of reducing blood sugar and preparation method of health-care flour |
| CN105456407A (en) * | 2015-12-16 | 2016-04-06 | 西安膳方医药科技有限公司 | Novel functional plant composition and application thereof |
| CN107307417A (en) * | 2017-06-17 | 2017-11-03 | 深圳市领治医学科技有限公司 | A kind of type 2 diabetes patient's nutriment |
| CN109043259A (en) * | 2018-07-31 | 2018-12-21 | 天津市圭谷科技发展有限公司 | A kind of ferment L-arabinose stachyose composite beverage underflow |
| US10631564B2 (en) | 2015-06-19 | 2020-04-28 | University Of Southern California | Enterically coated microparticle compositions and methods for modified nutrient delivery |
| CN111227254A (en) * | 2020-02-27 | 2020-06-05 | 赫斯提亚健康科技(无锡)有限公司 | Carbohydrate composition for assisting in reducing blood sugar |
| US10744070B2 (en) | 2015-06-19 | 2020-08-18 | University Of Southern California | Enteral fast access tract platform system |
| CN112006207A (en) * | 2020-09-04 | 2020-12-01 | 吴珩 | Compound dietary fiber beverage and preparation method thereof |
| CN113951415A (en) * | 2021-10-15 | 2022-01-21 | 山东轻能生物科技有限责任公司 | Composite water-soluble dietary fiber solid beverage for regulating intestinal flora and relieving liver fat accumulation |
| CN114651982A (en) * | 2022-03-22 | 2022-06-24 | 北大荒完达山乳业股份有限公司 | Composition capable of delaying postprandial blood sugar, preparation method and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012077038A1 (en) * | 2010-12-06 | 2012-06-14 | Degama Berrier Ltd. | Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof |
| CN102630948A (en) * | 2012-04-19 | 2012-08-15 | 保龄宝生物股份有限公司 | High-fiber sugar-free fruit flavored type compound prebiotics and preparation method thereof |
| CN102771751A (en) * | 2012-07-13 | 2012-11-14 | 常小勇 | Edible compound stevioside for diabetes patients |
| CN102987028A (en) * | 2012-12-18 | 2013-03-27 | 叶文飚 | Herbal tea containing L-arabinose |
| CN103284038A (en) * | 2012-12-27 | 2013-09-11 | 福建永生活力生物工程有限公司 | Hyperglycemic composition and preparation method thereof |
| CN103815225A (en) * | 2013-08-27 | 2014-05-28 | 常小勇 | Combination suitable for being eaten by people suffering from diabetes and adiposis and preparation method thereof |
| CN103965377A (en) * | 2014-05-14 | 2014-08-06 | 东南大学 | Method for preparing synanthrin from jerusalem artichoke |
-
2014
- 2014-09-02 CN CN201410440468.2A patent/CN104187670A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012077038A1 (en) * | 2010-12-06 | 2012-06-14 | Degama Berrier Ltd. | Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof |
| CN102630948A (en) * | 2012-04-19 | 2012-08-15 | 保龄宝生物股份有限公司 | High-fiber sugar-free fruit flavored type compound prebiotics and preparation method thereof |
| CN102771751A (en) * | 2012-07-13 | 2012-11-14 | 常小勇 | Edible compound stevioside for diabetes patients |
| CN102987028A (en) * | 2012-12-18 | 2013-03-27 | 叶文飚 | Herbal tea containing L-arabinose |
| CN103284038A (en) * | 2012-12-27 | 2013-09-11 | 福建永生活力生物工程有限公司 | Hyperglycemic composition and preparation method thereof |
| CN103815225A (en) * | 2013-08-27 | 2014-05-28 | 常小勇 | Combination suitable for being eaten by people suffering from diabetes and adiposis and preparation method thereof |
| CN103965377A (en) * | 2014-05-14 | 2014-08-06 | 东南大学 | Method for preparing synanthrin from jerusalem artichoke |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104939082A (en) * | 2015-06-02 | 2015-09-30 | 西安膳方医药科技有限公司 | Composite prebiotic and preparation method thereof |
| US10631564B2 (en) | 2015-06-19 | 2020-04-28 | University Of Southern California | Enterically coated microparticle compositions and methods for modified nutrient delivery |
| US10744070B2 (en) | 2015-06-19 | 2020-08-18 | University Of Southern California | Enteral fast access tract platform system |
| CN105341641A (en) * | 2015-09-28 | 2016-02-24 | 河南科技大学 | Health-care flour capable of reducing blood sugar and preparation method of health-care flour |
| CN105456407A (en) * | 2015-12-16 | 2016-04-06 | 西安膳方医药科技有限公司 | Novel functional plant composition and application thereof |
| CN107307417A (en) * | 2017-06-17 | 2017-11-03 | 深圳市领治医学科技有限公司 | A kind of type 2 diabetes patient's nutriment |
| CN109043259A (en) * | 2018-07-31 | 2018-12-21 | 天津市圭谷科技发展有限公司 | A kind of ferment L-arabinose stachyose composite beverage underflow |
| CN111227254A (en) * | 2020-02-27 | 2020-06-05 | 赫斯提亚健康科技(无锡)有限公司 | Carbohydrate composition for assisting in reducing blood sugar |
| CN112006207A (en) * | 2020-09-04 | 2020-12-01 | 吴珩 | Compound dietary fiber beverage and preparation method thereof |
| CN113951415A (en) * | 2021-10-15 | 2022-01-21 | 山东轻能生物科技有限责任公司 | Composite water-soluble dietary fiber solid beverage for regulating intestinal flora and relieving liver fat accumulation |
| CN114651982A (en) * | 2022-03-22 | 2022-06-24 | 北大荒完达山乳业股份有限公司 | Composition capable of delaying postprandial blood sugar, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104187670A (en) | Special dietary formula for assisting patients with diabetes in regulating blood sugar | |
| CN101933568B (en) | Low-heat nutrient heal-care sugar and production method thereof | |
| CN104187709A (en) | Total nutrient formula food suitable for patients having obesity or fat-reducing operation | |
| CN109619358A (en) | A kind of solid drinks and preparation method thereof based on soybean peptide albumen powder | |
| CN105532869A (en) | Cane sugar-free flavor fermented milk for continuously providing energy and preparation method thereof | |
| CN104187708A (en) | Total-nutrient formulated food for patients with diabetes | |
| CN104643250A (en) | Solid beverage capable of bidirectionally regulating body weight and improving subhealth | |
| CN104839664A (en) | Medical formula food for osteoporosis | |
| CN102511861A (en) | Thickened red jujube pulp added with oligosaccharide | |
| CN106690331A (en) | Kelp dietary fiber granules and preparation method thereof | |
| CN104187632A (en) | Total-nutrient formulated food eaten by patients with osteoporosis | |
| CN102511864B (en) | Jujube high-consistency stock | |
| CN103907994B (en) | A kind of prebiotics green juice powder of nursing one's health enteron aisle | |
| CN110140971A (en) | A kind of water-soluble dietary fiber | |
| CN104256642A (en) | Fully nutrient formula food for lowering high blood pressure, high blood sugar and high blood lipid and strengthening yang | |
| CN103284265A (en) | Solid beverage with effects of improving intestinal flora and relaxing bowels | |
| CN102415465A (en) | Preparation method of bifidus factor QQ candy containing erythritol | |
| CN101176553A (en) | Fresh fruit konjak functional food and preparation method thereof | |
| CN114128813A (en) | Beverage for relieving alcoholism and protecting liver and promoting vitality of liver and preparation method thereof | |
| US20190262415A1 (en) | Supplement for inducing and sustaining nutritional ketosis | |
| CN107198246A (en) | A kind of health composition and a kind of health care preparation | |
| CN104187641A (en) | Total nutrient formula food for phlegm-dampness constitution | |
| CN105146668A (en) | Deer blood polypeptide solid beverage | |
| CN114711374A (en) | Composite nutrient powder of ferment fibre and its preparation method | |
| CN104187643A (en) | All-nutrition formula food for yang-deficiency constitution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141210 |